Neuropace/NPCE

$13.98

-0.43%
-
1D1W1MYTD1YMAX

About Neuropace

NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.

Ticker

NPCE

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Frank Fischer

Employees

171

Headquarters

Mountain view, United States

Neuropace Metrics

BasicAdvanced
$379.82M
Market cap
-
P/E ratio
-$1.28
EPS
-
Beta
-
Dividend rate
$379.82M
$18.15
$3.80
108.57K
5.713
5.022
275.753
275.753
-4.97%
-29.72%
-118.91%
-33.88%
5.806
18.051
18.39
43.72%
33.06%
16.72%

What the Analysts think about Neuropace

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
27.54% upside
High $20.00
Low $13.00
$13.98
Current price
$17.83
Average price target

Neuropace Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-34.44% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$18M
9.76%
Net income
$-6.2M
-13.89%
Profit margin
-34.44%
-21.55%

Neuropace Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 26.98%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.41
-$0.36
-$0.28
-$0.23
-
Expected
-$0.46
-$0.47
-$0.41
-$0.32
-$0.32
Surprise
-10.09%
-22.58%
-31.71%
-26.98%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Neuropace stock?

Neuropace (NPCE) has a market cap of $379.82M as of April 17, 2024.

What is the P/E ratio for Neuropace stock?

The price to earnings (P/E) ratio for Neuropace (NPCE) stock is 0 as of April 17, 2024.

Does Neuropace stock pay dividends?

No, Neuropace (NPCE) stock does not pay dividends to its shareholders as of April 17, 2024.

When is the next Neuropace dividend payment date?

Neuropace (NPCE) stock does not pay dividends to its shareholders.

What is the beta indicator for Neuropace?

Neuropace (NPCE) does not currently have a Beta indicator.

What is the Neuropace stock price target?

The target price for Neuropace (NPCE) stock is $17.83, which is 27.54% above the current price of $13.98. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Neuropace stock

Buy or sell Neuropace stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing